These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17474556)

  • 1. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease.
    Cottone S; Nardi E; Mulè G; Vadalà A; Lorito MC; Riccobene R; Palermo A; Arsena R; Guarneri M; Cerasola G
    Clin Nephrol; 2007 Apr; 67(4):209-16. PubMed ID: 17474556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular hypertrophy and endothelial dysfunction in chronic kidney disease.
    Poulikakos D; Ross L; Recio-Mayoral A; Cole D; Andoh J; Chitalia N; Sharma R; Carlos Kaski J; Banerjee D
    Eur Heart J Cardiovasc Imaging; 2014 Jan; 15(1):56-61. PubMed ID: 23811493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Changes and Their Association with Fetuin-A and Fibroblast Growth Factor-23 in Children with Chronic Kidney Disease.
    Mudi A; Ntsinjana H; Dickens C; Levy C; Ballot D
    Nephron; 2017; 136(3):233-242. PubMed ID: 28402974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?
    López B; González A; Lasarte JJ; Sarobe P; Borrás F; Díaz A; Barba J; Tomás L; Lozano E; Serrano M; Varo N; Beloqui O; Fortuño MA; Díez J
    J Hypertens; 2005 Mar; 23(3):625-32. PubMed ID: 15716706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma neutrophil gelatinase-associated lipocalin is independently associated with left ventricular hypertrophy and diastolic dysfunction in patients with chronic kidney disease.
    Kim IY; Kim JH; Kim MJ; Lee DW; Hwang CG; Han M; Rhee H; Song SH; Seong EY; Lee SB
    PLoS One; 2018; 13(10):e0205848. PubMed ID: 30325973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of left ventricular hypertrophy in chronic kidney disease: an echocardiographic evaluation.
    Sambi RS; Gaur AK; Hotchandani R; Aggarwal KK; Kaur S; Gupta M; Jain S; Krishna CK; Chopra HK; Anand V; Srivastava S; Gupta R; Parashar SK
    Indian Heart J; 2011; 63(3):259-68. PubMed ID: 22734347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An association between inflammatory state and left ventricular hypertrophy in hemodialysis patients.
    Erten Y; Tulmac M; Derici U; Pasaoglu H; Altok Reis K; Bali M; Arinsoy T; Cengel A; Sindel S
    Ren Fail; 2005; 27(5):581-9. PubMed ID: 16152997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of left ventricular hypertrophy with high-sensitive C-reactive protein in hemodialysis patients.
    Monfared A; Salari A; Kazemnezhad E; Lebadi M; Khosravi M; Mehrjardi NK; Rahimifar S; Amini N
    Int Urol Nephrol; 2013 Dec; 45(6):1679-86. PubMed ID: 23306861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings from the CRIC Study.
    Gupta J; Dominic EA; Fink JC; Ojo AO; Barrows IR; Reilly MP; Townsend RR; Joffe MM; Rosas SE; Wolman M; Patel SS; Keane MG; Feldman HI; Kusek JW; Raj DS;
    PLoS One; 2015; 10(4):e0124772. PubMed ID: 25909952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.
    Paoletti E; De Nicola L; Gabbai FB; Chiodini P; Ravera M; Pieracci L; Marre S; Cassottana P; Lucà S; Vettoretti S; Borrelli S; Conte G; Minutolo R
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):271-9. PubMed ID: 26668021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 18 as a new inflammatory mediator in left ventricular hypertrophy in children with end-stage renal disease.
    Badawy A; Nigm DA; Ezzat GM; Gamal Y
    Saudi J Kidney Dis Transpl; 2020; 31(6):1206-1216. PubMed ID: 33565432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between High-Sensitivity Cardiac Troponin T and Echocardiographic Parameters in Chronic Kidney Disease: Results From the KNOW-CKD Cohort Study.
    Kang E; Ryu H; Kim J; Lee J; Lee KB; Chae DW; Sung SA; Kim SW; Ahn C; Oh KH
    J Am Heart Assoc; 2019 Sep; 8(18):e013357. PubMed ID: 31514574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of the serum levels of serum troponins I and T, albumin and C-Reactive protein in chronic hemodialysis patients and their relationship with left ventricular hypertrophy and heart failure.
    Forghani MS; Jadidoleslami MS; Naleini SN; Rajabnia M
    Diabetes Metab Syndr; 2019; 13(1):522-525. PubMed ID: 30641758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the role of cardiovascular biomarkers in children with pre-dialysis chronic kidney disease: a substitute to echocardiography to detect increased left ventricular mass?
    Clothier JC; Simpson JM; Turner C; Dalton RN; Rasmussen P; Rawlins D; Booth CJ; Peacock JL; Sinha MD
    Nephron Clin Pract; 2013; 124(3-4):191-201. PubMed ID: 24401719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension.
    Navarro-González JF; Mora C; Muros M; Jarque A; Herrera H; García J
    J Hypertens; 2008 Nov; 26(11):2168-75. PubMed ID: 18854757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular hypertrophy in nondiabetic predialysis CKD.
    Paoletti E; Bellino D; Cassottana P; Rolla D; Cannella G
    Am J Kidney Dis; 2005 Aug; 46(2):320-7. PubMed ID: 16112052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risk factors and pathogenetic mechanisms of left ventricular hypertrophy in progressive chronic kidney disease and after transplantation of the kidney].
    Tomilina NA; Storozhakov GI; Gendlin GE; Badaeva SV; Zhidkova DA; Kim IG; Borisovskaia SV; Loss KE; Fedorova ND
    Ter Arkh; 2007; 79(6):34-40. PubMed ID: 17684964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications.
    Calò LA; Vertolli U; Pagnin E; Ravarotto V; Davis PA; Lupia M; Naso E; Maiolino G; Naso A
    Life Sci; 2016 Mar; 148():80-5. PubMed ID: 26872982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study.
    Nitta K; Iimuro S; Imai E; Matsuo S; Makino H; Akizawa T; Watanabe T; Ohashi Y; Hishida A
    Clin Exp Nephrol; 2019 Jan; 23(1):85-98. PubMed ID: 29951723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese.
    Lin Z; Zhou Z; Liu Y; Gong Q; Yan X; Xiao J; Wang X; Lin S; Feng W; Li X
    PLoS One; 2011 Apr; 6(4):e18398. PubMed ID: 21525989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.